Haemodialysis fMRI Salt Appetite Study (HeMSA)

Imperial College London

Status

Enrolling

Conditions

Excess Interdialytic Weight Gain

Dialysis

Treatments

Procedure: haemodialysis

Study type

Observational

Funder types

Other

Identifiers

NCT04011254

19HH5153

Details and patient eligibility

About

Assessing how the rapid removal of salt and water by haemodialysis alters regional brain activity (by measurement of the brain blood oxygen level-dependent (BOLD) signal using functional MRI) during tasting of soup of differing salt concentrations.
Identify differences in the brain response to salt taste pre- and post-haemodialysis between haemodialysis patients who are either able or unable to control between dialysis weight gain

Full description

HeMSA Study Phase 2 Up to 20 male, haemodialysis patient who have average %IDWG >4% will be recruited with the target, to proceed to scanning, of 14 patients. Following consent the patients will complete questionnaires (including Salt intake questionnaire - DSQ (Gkza and Davenport, 2017), Edinburgh handedness questionnaire (Oldfield, 1971), MRI checklist) and undergo salt taste preference and threshold testing during a 1 hour session prior to dialysis. The purpose of this visit is to establish the tasteless solution and 2 soup salt concentrations to be used in the salt taste fMRI paradigm, obtain baseline data regarding estimate of salt intake and ensure MRI is safe for this patient.

Patients will then attend 2 MRI scanning visits at the Hammersmith Hospital Imperial Campus, one the morning immediately before haemodialysis and one the morning after haemodialysis. Prior to the MRI session, at the Imperial College Clinical Research Facility, the patient will undergo various clinical assessments and have venous blood samples taken. The MRI will be undertaken at the Imperial College Clinical Imaging Facility using a Siemens 3T Verio scanner. During the scan subjects will taste, via a taste delivery system, aliquots of tasteless solution, sucralose, and 2 soup with different concentrations of salt. Solutions will be delivered in a block design.

HeMSA Study Phase 3 3 groups (healthy controls, haemodialysis (HD) patients with %IDWG <4%, haemodialysis patients with %IDWG >4% - patients froms phase 2 will contribute to the latter group) Protocol will follow that for HeMSA Phase 2. Healthy controls will also have 2 study visits at a similar period apart to the HD participants.

Enrollment

90 estimated patients

Sex

Male

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

All participants:

Male
Aged 18-65 years
Non-smoker (ex-smokers allowed)
Right handed (able to use a right handed response button)
Able to tolerate 1 hour MRI scanning session

For haemodialysis patients:

Established on haemodialysis for more than 6 months
Urine output <200ml/24 hours
Average (over the past month) interdialytic weight gain:
1. Main phase 2: >4 %IDWG
2. Main phase 3: <4 or >4 %IDWG

Exclusion criteria

Type 1 or type 2 diabetes mellitus
Current smoker
Uncontrolled depression (change in use of anti-depressants in last 3 months, or BDI-II score >28/63)
Neurological disorder (Parkinson's disease, serious cerebrovascular disease, epilepsy, moderate-severe traumatic brain injury, dementia)
Previous bariatric surgery
Inflammatory state (CRP >20 on routine dialysis blood tests)
Acute infective illness
Significant current or past medical or psychiatric history, or use of medications, that, in the opinion of the Investigators, contraindicates their participation, due to influence on outcome measures.
Patients lacking capacity or unable to consent and non-English language speakers
Contra-indication to MRI imaging e.g. metal insert, pacemaker
Claustrophobia
Patients currently participating in an active CTIMP trial, or within 4 half-lives of last administration of CTIMP product
Serious mental illness (e.g. bipolar disorder, schizophrenia)
Current alcohol or drug dependence